Project Grant R01NS144029
Award Date
8/1/25
Completion Date
6/30/30
Dollars Obligated
$628K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $687,279 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to conduct research on dissecting the orchestrated immune responses to glioblastoma within the native tissue microenvironment. The goal is to improve treatment outcomes by advancing the understanding of the diversity,...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $1,267,312 to Brigham & Women's Hospital Inc. to conduct research aimed at improving intratumoral IL12 immunogene therapy for glioblastoma. The research project will explore two key questions: 1) whether the timing of immune checkpoint inhibitor (ICI) administration changes the...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $472,124 to Beth Israel Deaconess Medical Center, Inc. to conduct exploratory studies on the role of TREM1 and TREM2 receptors in the immune response to glioblastoma, an aggressive form of brain cancer. The research aims to use a novel mouse model of glioblastoma to investigate how...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,217,078 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to record neural activity in the intact human brain to better understand tumor infiltration. The project will utilize cutting-edge high-resolution microelectrodes, including 1,000-channel thin-film...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to develop an encapsulated cell-based oncolytic virus therapy for brain tumors, specifically glioblastoma (GBM). The $420,251 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, will fund the development and testing of mesenchymal stem...
This $195,896 Project Grant, awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to define the circuit connectivity between glioblastoma, a fatal brain cancer, and diverse neuronal populations in the mouse brain. The research aims to elucidate the role of cholinergic neuromodulatory inputs in regulating glioma progression, with the goal of...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $717,802 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the University of Georgia Research Foundation, Inc. The grant supports research aimed at elucidating the cellular and molecular mechanisms underlying the development of a subtype of high-grade glioma brain tumors known as HGG-G34. Specifically, the research project seeks to unravel the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The General Hospital Corporation, doing business as Massachusetts General Hospital, to conduct a Phase I clinical trial evaluating the safety and feasibility of CARV3.TEAM-E cells for the treatment of primary or recurrent glioblastoma (GBM), a deadly brain tumor. The CARV3.TEAM-E cells are genetically engineered chimeric antigen receptor (CAR) T cells that target the...
This federal Project Grant award, totaling $653,192.00 and provided by the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders, supports a longitudinal study on non-invasive imaging of pathological fibrin deposition and its effects on progressive neurodegeneration in the human brain. The study, conducted by the primary awardee The General Hospital Corporation (doing business as...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $771,627 project grant to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct advanced biomedical research on tuning and strike targeting of glioblastoma. The 24-month award period runs from August 1, 2025 to July 31, 2027. As a leading academic medical center and recipient of significant federal research funding, Massachusetts General Hospital will...